{"type":"trials","record":{"id":41594,"source_id":"clinicaltrials-gov","external_id":"NCT07053358","title":"Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients","brief_summary":"The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.","overall_status":"Recruiting","phases":["EARLY_PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","enrollment":10,"countries":["China"],"start_date":"2025-07-02","completion_date":"2029-12-30","last_update_date":"2026-03-10","source_url":"https://clinicaltrials.gov/study/NCT07053358","editorial_summary":"A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","interventions":["LX111 Injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Adverse events and serious adverse events in the eyes and throughout the body within 364 days after LX111 treatment — 5…","Dose Limiting Toxicity — 4 weeks","Mean changes in BCVA from Baseline — 12 weeks, 36 weeks, 52 weeks","Mean changes in Central Subfield Thickness (CST) from Baseline — 12 weeks, 36 weeks, 52 weeks","The percentage of subjects who received anti-VEGF supplemental injection within 52 weeks after LX111 treatment — 52 wee…"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","LX111 Injection"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07053358","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-07-02 to 2029-12-30","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.838Z","intervention":["LX111 Injection"],"participants":10,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"EARLY_PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Adverse events and serious adverse events in the eyes and throughout the body within 364 days after LX111 treatment — 5…","Dose Limiting Toxicity — 4 weeks","Mean changes in BCVA from Baseline — 12 weeks, 36 weeks, 52 weeks","Mean changes in Central Subfield Thickness (CST) from Baseline — 12 weeks, 36 weeks, 52 weeks","The percentage of subjects who received anti-VEGF supplemental injection within 52 weeks after LX111 treatment — 52 wee…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41594","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}